AIM ImmunoTech
About: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Employees: 28
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0.85% more ownership
Funds ownership: 14.93% [Q2] → 15.77% (+0.85%) [Q3]
8% less funds holding
Funds holding: 36 [Q2] → 33 (-3) [Q3]
24% less capital invested
Capital invested by funds: $3.18M [Q2] → $2.41M (-$773K) [Q3]
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
411%
upside
Avg. target
$2.75
1,306%
upside
High target
$4.50
2,201%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 36% 1-year accuracy 26 / 73 met price target | 2,201%upside $4.50 | Buy Maintained | 10 Dec 2024 |
Maxim Group Jason McCarthy 33% 1-year accuracy 9 / 27 met price target | 411%upside $1 | Buy Maintained | 22 Oct 2024 |
Financial journalist opinion
Based on 17 articles about AIM published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
OCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated December 11, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards.
Neutral
Business Wire
1 week ago
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elected three of the Company's incumbent directors – Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell – to the Board of Directors (the “Board”) at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) held today. Additionally, Ted D. Kellner was elected to the Board. Dr. William M.
Neutral
Business Wire
1 week ago
AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024 at 11:00 a.m. ET: AIM urges shareholders to protect their investment and the Company's future by voting on the WHITE universal proxy card “FOR” all four current members of our Board of Directors (the “Board”). AIM is confident that.
Neutral
GlobeNewsWire
1 week ago
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board
Vote “ FOR ” All Four Kellner Group Nominees Today on Gold Card for Urgently Needed Change
Neutral
Business Wire
1 week ago
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024: With the Annual Meeting quickly approaching, it is critical that shareholders vote on the WHITE universal proxy card to re-elect all four current members of our Board of Directors (the “Board”). As shareholders consider this import.
Neutral
GlobeNewsWire
2 weeks ago
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 — a compositions and methods patent — covering Ampligen® (rintatolimod) for use in the treatment of the post-COVID condition of fatigue. The patent inventors, AIM CEO Thomas K. Equels and AIM Medical Officer David R. Strayer, M.D., have assigned the granted patent to the Company.
Neutral
GlobeNewsWire
2 weeks ago
Kellner Group Announces Support from Another Former AIM Senior Executive
NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the “Kellner Group,” “we” or “us” and, as nominees, the “Kellner Group Nominees”) today issue the following press release in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE American: AIM).
Neutral
GlobeNewsWire
2 weeks ago
AIM's Clinical Strategy Under Incumbent Board Has Totally Failed
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the “Kellner Group,” “we” or “us” and, as nominees, the “Kellner Group Nominees”) today issue the following press release in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE American: AIM).
Neutral
Business Wire
2 weeks ago
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended that shareholders vote “FOR” Company nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024. In reaching its recommendation against giving the activist inves.
Neutral
GlobeNewsWire
2 weeks ago
Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W.
Charts implemented using Lightweight Charts™